Geron Corporation (GERN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

SA Transcripts158.9K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Geron Corporation (GERN) Barclays 28th Annual Global Healthcare Conference March 10, 2026 10:30 AM EDT Company Participants Harout Semerjian - CEO, President & DirectorJoseph Eid - Executive VP of Research & Development and Chief Medical Officer Conference Call Participants Nicole Germino Presentation Nicole Germino All right. Good morning, everyone. I'm Nicole Germino, one of the biopharma investment bankers here at Barclays. And today, we are joined by Harout Semerjian, President and CEO; and Joseph Eid, Executive Vice President of Research and Development and CMO of Geron. Thank you both so much for being here today. So Harout, to kick us off, you have a robust experience in big pharma and biotech. What are the reasons that attracted you to Geron? Since joining the company in August of last year, what has the company done in 2026 to align Geron for success? Harout SemerjianCEO, President & Director Yes. Thank you very much, Nicole, and thanks for Barclays for -- this is a very nice invitation and the opportunity to continue to share our Geron story. Yes, you're right. I've been in pharma for more than 30 years between pharma, biotech and particularly in hematology/oncology for 20-plus years. And really what attracted me to Geron and what keeps me motivated 6 months in is a drug that works. First of all, imetelstat, a new option for lower-risk MDS patients and really one where we can actually make a difference for even more patients with a more robust and refined commercialization plan. And that's what we've been doing over the last few months and really making sure that we are reaching more and more patients. In 2025, we did announce that overall in the year, we have in our first full commercial year, sold $184 million of sales, which is a very good starting point. But more